 Seelos Therapeutics, Inc. NASDAQ: SEEL shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an 8 price target. Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. 